{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+2&page=42", "query": { "intervention": "Capsule 2", "page": 42 }, "page_size": 10 }, "pagination": { "page": 42, "page_size": 10, "total_count": 5059, "total_pages": 506, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+2&page=43&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+2&page=41&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T17:33:24.670Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05738850", "title": "Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Generalized Anxiety Disorder (GAD)", "Healthy Participants" ], "interventions": [ { "name": "ABBV-932", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 104, "start_date": "2023-02-15", "completion_date": "2024-05-31", "has_results": false, "last_update_posted_date": "2024-07-01", "last_synced_at": "2026-11-06T17:33:24.670Z", "location_count": 2, "location_summary": "Anaheim, California • Grayslake, Illinois", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Grayslake", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05738850" }, { "nct_id": "NCT01279590", "title": "Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myalgia", "Hypercholesterolemia", "Hyperlipidemia" ], "interventions": [ { "name": "PPD10558", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Furiex Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 282, "start_date": "2011-03", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2011-12-22", "last_synced_at": "2026-11-06T17:33:24.670Z", "location_count": 67, "location_summary": "Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Huntington Park", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01279590" }, { "nct_id": "NCT02349048", "title": "Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Simeprevir 150 mg", "type": "DRUG" }, { "name": "Daclatasvir 60 mg", "type": "DRUG" }, { "name": "Sofosbuvir 400 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 68, "start_date": "2015-01", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-03-01", "last_synced_at": "2026-11-06T17:33:24.670Z", "location_count": 7, "location_summary": "Bakersfield, California • Jacksonville, Florida • Lutherville, Maryland + 4 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Lutherville", "state": "Maryland" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02349048" }, { "nct_id": "NCT00573443", "title": "Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pseudobulbar Affect (PBA)" ], "interventions": [ { "name": "dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg", "type": "DRUG" }, { "name": "dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avanir Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 326, "start_date": "2007-12", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2017-04-12", "last_synced_at": "2026-11-06T17:33:24.670Z", "location_count": 45, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00573443" }, { "nct_id": "NCT05099276", "title": "Extended Postoperative Oral Tranexamic Acid in Knee Replacement", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Knee Osteoarthritis", "Blood Loss", "Pain, Postoperative" ], "interventions": [ { "name": "Tranexamic Acid Pill", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Campbell Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 46, "start_date": "2021-12-07", "completion_date": "2024-06-01", "has_results": false, "last_update_posted_date": "2024-03-06", "last_synced_at": "2026-11-06T17:33:24.670Z", "location_count": 1, "location_summary": "Germantown, Tennessee", "locations": [ { "city": "Germantown", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05099276" }, { "nct_id": "NCT03685591", "title": "PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Neoplasms", "Prostate Neoplasms", "Neoplasms, Squamous Cell", "Melanoma", "Mesothelioma", "Pancreatic Neoplasms", "Colorectal Neoplasms", "Carcinoma, Renal Cell", "Liver Neoplasms" ], "interventions": [ { "name": "PF-06952229", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2018-10-04", "completion_date": "2022-03-30", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-11-06T17:33:24.670Z", "location_count": 15, "location_summary": "Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03685591" }, { "nct_id": "NCT01556763", "title": "Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder", "Central Nervous System Diseases" ], "interventions": [ { "name": "EVP-6124 (0.3 mg/day)", "type": "DRUG" }, { "name": "EVP-6124 (1.0 mg/day)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Antipsychotic therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "FORUM Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 21, "start_date": "2008-04", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2012-06-21", "last_synced_at": "2026-11-06T17:33:24.670Z", "location_count": 1, "location_summary": "Wichita, Kansas", "locations": [ { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01556763" }, { "nct_id": "NCT04564547", "title": "Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Islatravir", "type": "DRUG" }, { "name": "Ulonivirine", "type": "DRUG" }, { "name": "BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to ISL", "type": "DRUG" }, { "name": "Placebo to Ulonivirine", "type": "DRUG" }, { "name": "Placebo to BIC/FTC/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2021-03-09", "completion_date": "2025-01-30", "has_results": true, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-11-06T17:33:24.670Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Los Angeles, California • Ft. Pierce, Florida + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04564547" }, { "nct_id": "NCT05995249", "title": "A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "TAK-279", "type": "DRUG" }, { "name": "Erythromycin", "type": "DRUG" }, { "name": "Phenytoin", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 172, "start_date": "2023-08-11", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2024-02-06", "last_synced_at": "2026-11-06T17:33:24.670Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05995249" }, { "nct_id": "NCT02812238", "title": "Study to Evaluate the Effect of Nicotinamide Riboside on Immunity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Atherosclerosis", "Diabetes", "Coronary Artery Disease" ], "interventions": [ { "name": "Nicotinamide riboside (NR)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 38, "start_date": "2016-06-23", "completion_date": "2018-08-28", "has_results": true, "last_update_posted_date": "2019-09-17", "last_synced_at": "2026-11-06T17:33:24.670Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02812238" } ] }